HighTower Advisors
MDGL icon

HighTower Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

HighTower Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$25K – 3924
2024
Q4 		$25K Buy
+200
New +$56.3K ﹤0.01% 3526
2024
Q2 		– Sell
-300
Closed -$41.7K – 3819
2024
Q1 		$41.7K Buy
+300
New +$70.7K ﹤0.01% 3278

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's MDGL Position: Q1 2026 in Review

HighTower Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 1,086% in Q1 2026, buying an estimated $6.09M and bringing the position to 13,914 shares worth $7.28M. The position accounts for 0.01% of the portfolio, ranked #1023.

HighTower Advisors first reported a position in MDGL in Q4 2022 and has held it in 11 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • HighTower Advisors held 13,914 shares of Madrigal Pharmaceuticals worth $7.28M as of Q1 2026.
  • HighTower Advisors bought 12,741 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $6.09M.
  • Madrigal Pharmaceuticals made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #1023 holding.
  • HighTower Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.